vs
Proto Labs Inc（PRLB）与VERACYTE, INC.（VCYT）财务数据对比。点击上方公司名可切换其他公司
Proto Labs Inc的季度营收约是VERACYTE, INC.的1.0倍（$139.3M vs $139.1M），VERACYTE, INC.净利率更高（20.6% vs 5.8%，领先14.8%），VERACYTE, INC.同比增速更快（21.5% vs 10.4%），过去两年VERACYTE, INC.的营收复合增速更高（10.2% vs 5.3%）
Proto Labs是一家提供快速制造服务的企业，可通过3D打印、CNC加工、钣金加工以及注塑成型工艺，为客户生产用于原型制作和量产的定制零部件，产品广泛应用于医疗设备、航空航天、电子、家电、汽车、消费品等多个领域，公司总部位于美国明尼苏达州，在美国多地设有生产基地。
Veracyte是一家领先的分子诊断企业，专注开发专有的基因组检测方案，可实现癌症及其他复杂疾病的早期精准检测，产品服务于医疗机构以优化临床决策，核心市场位于美国，正稳步拓展全球业务布局。
PRLB vs VCYT — 直观对比
营收规模更大
PRLB
是对方的1.0倍
$139.1M
营收增速更快
VCYT
高出11.1%
10.4%
净利率更高
VCYT
高出14.8%
5.8%
两年增速更快
VCYT
近两年复合增速
5.3%
损益表 — Q1 FY2026 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $139.3M | $139.1M |
| 净利润 | $8.1M | $28.7M |
| 毛利率 | 45.6% | 72.7% |
| 营业利润率 | 7.1% | 16.3% |
| 净利率 | 5.8% | 20.6% |
| 营收同比 | 10.4% | 21.5% |
| 净利润同比 | 125.4% | — |
| 每股收益（稀释后） | $0.29 | $0.35 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PRLBVCYT
| Q1 26 | $139.3M | $139.1M | ||
| Q4 25 | $136.5M | $140.6M | ||
| Q3 25 | $135.4M | $131.9M | ||
| Q2 25 | $135.1M | $130.2M | ||
| Q1 25 | $126.2M | $114.5M | ||
| Q4 24 | $121.8M | $118.6M | ||
| Q3 24 | $125.6M | $115.9M | ||
| Q2 24 | $125.6M | $114.4M |
净利润PRLBVCYT
| Q1 26 | $8.1M | $28.7M | ||
| Q4 25 | — | $41.1M | ||
| Q3 25 | $7.2M | $19.1M | ||
| Q2 25 | $4.4M | $-980.0K | ||
| Q1 25 | $3.6M | $7.0M | ||
| Q4 24 | — | $5.1M | ||
| Q3 24 | $7.2M | $15.2M | ||
| Q2 24 | $4.5M | $5.7M |
毛利率PRLBVCYT
| Q1 26 | 45.6% | 72.7% | ||
| Q4 25 | 44.2% | 72.5% | ||
| Q3 25 | 45.3% | 69.2% | ||
| Q2 25 | 44.3% | 69.0% | ||
| Q1 25 | 44.1% | 69.5% | ||
| Q4 24 | 42.7% | 66.4% | ||
| Q3 24 | 45.6% | 68.2% | ||
| Q2 24 | 45.0% | 68.1% |
营业利润率PRLBVCYT
| Q1 26 | 7.1% | 16.3% | ||
| Q4 25 | 5.0% | 26.4% | ||
| Q3 25 | 6.5% | 17.4% | ||
| Q2 25 | 3.7% | -4.0% | ||
| Q1 25 | 3.6% | 2.5% | ||
| Q4 24 | -1.2% | 3.5% | ||
| Q3 24 | 6.8% | 10.4% | ||
| Q2 24 | 4.8% | 4.0% |
净利率PRLBVCYT
| Q1 26 | 5.8% | 20.6% | ||
| Q4 25 | — | 29.3% | ||
| Q3 25 | 5.3% | 14.5% | ||
| Q2 25 | 3.3% | -0.8% | ||
| Q1 25 | 2.9% | 6.2% | ||
| Q4 24 | — | 4.3% | ||
| Q3 24 | 5.7% | 13.1% | ||
| Q2 24 | 3.6% | 5.0% |
每股收益（稀释后）PRLBVCYT
| Q1 26 | $0.29 | $0.35 | ||
| Q4 25 | $0.25 | $0.50 | ||
| Q3 25 | $0.30 | $0.24 | ||
| Q2 25 | $0.18 | $-0.01 | ||
| Q1 25 | $0.15 | $0.09 | ||
| Q4 24 | $-0.01 | $0.07 | ||
| Q3 24 | $0.29 | $0.19 | ||
| Q2 24 | $0.18 | $0.07 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $124.0M | $439.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $683.1M | $1.3B |
| 总资产 | $778.6M | $1.4B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资PRLBVCYT
| Q1 26 | $124.0M | $439.1M | ||
| Q4 25 | $128.1M | $362.6M | ||
| Q3 25 | $119.2M | $315.6M | ||
| Q2 25 | $103.2M | $219.5M | ||
| Q1 25 | $96.8M | $186.1M | ||
| Q4 24 | $103.1M | $239.1M | ||
| Q3 24 | $100.5M | $274.1M | ||
| Q2 24 | $112.9M | $235.9M |
股东权益PRLBVCYT
| Q1 26 | $683.1M | $1.3B | ||
| Q4 25 | $673.9M | $1.3B | ||
| Q3 25 | $664.7M | $1.3B | ||
| Q2 25 | $664.7M | $1.2B | ||
| Q1 25 | $656.8M | $1.2B | ||
| Q4 24 | $670.2M | $1.2B | ||
| Q3 24 | $680.0M | $1.2B | ||
| Q2 24 | $685.2M | $1.1B |
总资产PRLBVCYT
| Q1 26 | $778.6M | $1.4B | ||
| Q4 25 | $763.4M | $1.4B | ||
| Q3 25 | $756.9M | $1.4B | ||
| Q2 25 | $743.3M | $1.3B | ||
| Q1 25 | $737.5M | $1.3B | ||
| Q4 24 | $743.5M | $1.3B | ||
| Q3 24 | $753.8M | $1.3B | ||
| Q2 24 | $758.2M | $1.2B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $17.5M | $35.2M |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | 2.16× | 1.23× |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流PRLBVCYT
| Q1 26 | $17.5M | $35.2M | ||
| Q4 25 | $16.5M | $52.6M | ||
| Q3 25 | $29.1M | $44.8M | ||
| Q2 25 | $10.6M | $33.6M | ||
| Q1 25 | $18.4M | $5.4M | ||
| Q4 24 | $17.3M | $24.5M | ||
| Q3 24 | $24.8M | $30.0M | ||
| Q2 24 | $14.4M | $29.6M |
自由现金流PRLBVCYT
| Q1 26 | — | — | ||
| Q4 25 | $8.4M | $48.8M | ||
| Q3 25 | $25.0M | $42.0M | ||
| Q2 25 | $9.1M | $32.3M | ||
| Q1 25 | $17.1M | $3.5M | ||
| Q4 24 | $16.5M | $20.4M | ||
| Q3 24 | $23.2M | $27.7M | ||
| Q2 24 | $10.2M | $26.8M |
自由现金流率PRLBVCYT
| Q1 26 | — | — | ||
| Q4 25 | 6.2% | 34.7% | ||
| Q3 25 | 18.5% | 31.8% | ||
| Q2 25 | 6.7% | 24.8% | ||
| Q1 25 | 13.6% | 3.1% | ||
| Q4 24 | 13.5% | 17.2% | ||
| Q3 24 | 18.5% | 23.9% | ||
| Q2 24 | 8.2% | 23.4% |
资本支出强度PRLBVCYT
| Q1 26 | — | — | ||
| Q4 25 | 5.9% | 2.7% | ||
| Q3 25 | 3.0% | 2.1% | ||
| Q2 25 | 1.1% | 1.0% | ||
| Q1 25 | 1.0% | 1.6% | ||
| Q4 24 | 0.7% | 3.5% | ||
| Q3 24 | 1.2% | 1.9% | ||
| Q2 24 | 3.3% | 2.4% |
现金转化率PRLBVCYT
| Q1 26 | 2.16× | 1.23× | ||
| Q4 25 | — | 1.28× | ||
| Q3 25 | 4.03× | 2.34× | ||
| Q2 25 | 2.39× | — | ||
| Q1 25 | 5.11× | 0.76× | ||
| Q4 24 | — | 4.80× | ||
| Q3 24 | 3.44× | 1.98× | ||
| Q2 24 | 3.18× | 5.16× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PRLB
| CNC Machining | $63.2M | 45% |
| Injection Molding | $51.1M | 37% |
| 3D Printing | $20.5M | 15% |
| Sheet Metal | $4.4M | 3% |
| Other Revenue | $207.0K | 0% |
VCYT
| Testing revenue | $135.1M | 97% |
| Product revenue | $3.7M | 3% |
| Biopharmaceutical and other revenue | $301.0K | 0% |
